Brief: Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing
31/12/2025 22:36
Dec 31 (Reuters) - Climb Bio Inc CLYM.O: CLIMB BIO INC - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILING CLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024 CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO'S BUDOPRUTUG DRUG CANDIDATE IS NOT "PRODUCT" UNDER APA CLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUG Source text: [ID:n0001193125-25-338318] Further company coverage: CLYM.O ((Reuters.Briefs@thomsonreuters.com;))